2023
DOI: 10.25259/ijdvl_744_2022
|View full text |Cite
|
Sign up to set email alerts
|

Recalcitrant chronic actinic dermatitis responding to tofacitinib: A case report

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(3 citation statements)
references
References 5 publications
0
3
0
Order By: Relevance
“…Tofacitinib, a selective oral Janus Kinase inhibitor (JAK1 inhibitor), has proven effective in treating several T cell-mediated dermatoses such as psoriasis, atopic dermatitis, dermatomyositis, alopecia areata, and vitiligo, which do not respond to classical immunosuppressive therapy. 7 , 19 , 21 Considering the growing evidence that Chronic Actinic Dermatitis (CAD) involves cytotoxic T cell activity inhibition of the JAK pathway holds potential as a therapeutic approach. In a case report by Dev et al, in which the patient exhibited persistent CAD and conventional medications had no effect, the decision to use tofacitinib was made.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Tofacitinib, a selective oral Janus Kinase inhibitor (JAK1 inhibitor), has proven effective in treating several T cell-mediated dermatoses such as psoriasis, atopic dermatitis, dermatomyositis, alopecia areata, and vitiligo, which do not respond to classical immunosuppressive therapy. 7 , 19 , 21 Considering the growing evidence that Chronic Actinic Dermatitis (CAD) involves cytotoxic T cell activity inhibition of the JAK pathway holds potential as a therapeutic approach. In a case report by Dev et al, in which the patient exhibited persistent CAD and conventional medications had no effect, the decision to use tofacitinib was made.…”
Section: Discussionmentioning
confidence: 99%
“…The observed sustained response suggests the potential of this drug for long-term control of CAD. 21 Vesely et al reported another case of severe CAD that did not respond to any of the following treatments: potent topical steroids, 0.1% tacrolimus ointment, prednisone, hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, omalizumab, acitretin, oral bexarotene, extracorporeal photopheresis, or various combinations of these treatments. Tofacitinib citrate was then decided upon, resulting in successful remission of the symptoms of the disease.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation